|

Onivyde Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Nanoliposomal irinotecan

Pipeline

Phase 1/2: 1

Top Sponsors

  • St. Jude Children's Research Hospital1

Indications

  • Refractory Soft Tissue Sarcoma1
  • Refractory Rhabdomyosarcoma1
  • Refractory Rhabdoid Tumor1
  • Refractory Peripheral Primitive Neuroectodermal Tumor1
  • Refractory Malignant Germ Cell Tumor1

Palo Alto, California1 trial

Study of Onivyde With Talazoparib or Temozolomide in Children With Recurrent Solid Tumors and Ewing Sarcoma

Lucille Packard Children's Hospital Stanford

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.